Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Δευτέρα 13 Νοεμβρίου 2017

A promising anti-prion trimethoxychalcone binds to the globular domain of PrPC and changes its cellular location [PublishAheadOfPrint]

The search for anti-prion compounds has been encouraged by the fact that transmissible spongiform encephalopathies (TSEs) share molecular mechanisms with more prevalent neurodegenerative pathologies, such as Parkinson's and Alzheimer's diseases. Cellular prion protein conversion into protease-resistant forms (PrPRes or PrPSc) is a critical step in the development of TSEs, thus being one of the main targets in the screening for anti-prion compounds. In this work, three trimethoxychalcones (J1, J8, J20) and one oxadiazole (Y17), previously identified in vitro as potential anti-prion compounds, were evaluated through different approaches in order to gain inferences about their mechanism of action. None of them changed PrPC mRNA levels in N2a cells as shown by RT-qPCR. Among them, J8 and Y17 were effective in RT-QuIC reactions using rodent rPrP23--231 as substrate and PrPSc seeds from hamster and human brain. However, when rPrP90--231, which lacks the N-terminal domain, was used as substrate, only J8 remained effective, indicating that this region is important for Y17 activity, while J8 seems to interact with PrPC globular domain. J8 also reduced the fibrillation of mouse rPrP23--231 seeded with in vitro-produced fibrils. Furthermore, most of the compounds decreased the amount of PrPC on N2a cell surface by trapping this protein in the endoplasmic reticulum. Based on these results, we hypothesize that J8, a non-toxic promising anti-prion compound as previously shown, may act by different mechanisms, since its efficacy is attributable not only to the PrP conversion inhibition, but also to reduction of PrPC content on the cell surface.



http://ift.tt/2zD6v5o

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.